Printer Friendly

CAMBRIDGE NEUROSCIENCE AWARDED PHASE II SBIR GRANT FOR SIXTH TIME; GRANT AWARDED TO FURTHER RESEARCH IN ION-CHANNEL BLOCKERS

 CAMBRIDGE, Mass., April 27 /PRNewswire/ -- Cambridge NeuroScience, Inc. (NASDAQ: CNSI) announced today that it has been awarded an NIH Phase II SBIR grant of $500,000 to develop ion-channel blockers as therapeutics to limit brain damage in brain ischemia (low blood flow).
 In an ischemic brain, glutamate is released in excess from energy deficient neurons that overstimulate nearby nerve cells. This initiates a biochemical cascade leading to the cell death responsible for the neurological deficits resulting from stroke, traumatic brain injury, and following major cardiac surgery. When given prophylactically, novel compounds that block the calcium and sodium channels (which control glutamate release) when given prophylactically should reduce the risk of neurological damage associated with a variety of cardiac surgeries and should limit neuronal damage when given after stroke or severe head injury.
 "The approval of this grant confirms our approach to this crucial area of medicine and the strength and breadth of our science. In the intensively competitive NIH peer review process, Cambridge NeuroScience has achieved success with all six of its Phase II grant applications," stated Robert McBurney, vice president, research. "This grant strengthens the company's leadership role in the area of ion-channel blockade as a way of treating diseases of the nervous system. It builds upon and complements the discovery of Cerestat(tm), an NMDA ion-channel blocker currently under investigation in stroke patients. That project was also supported, in part, by a Phase II grant."
 Cambridge NeuroScience is a leading neuroscience company engaged in the discovery and development of patented pharmaceuticals with a focus on nerve cell survival. The company is developing a number of products to treat stroke, traumatic brain injury and chronic neurodegenerative disorders such as diabetic peripheral neuropathy and multiple sclerosis. It also has complementary development programs for the treatment of schizophrenia and depression.
 -0- 4/27/93
 /CONTACT: Robert N. McBurney, vice president, research, 617-225-0600, ext. 114; Philip V. Holberton, chief financial officer, 617-225-0600, ext. 106, both of Cambridge NeuroScience/
 (CNSI)


CO: Cambridge NeuroScience, Inc. ST: Massachusetts IN: MTC SU:

DJ -- NE003 -- 1131 04/27/93 08:15 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 27, 1993
Words:345
Previous Article:SMITH'S FOOD & DRUG CENTERS REPORTS INCREASED SALES AND NET INCOME FOR FIRST QUARTER 1993
Next Article:T CELL SCIENCES RECEIVES NOTICE THAT A FUNDAMENTAL U.S. TCAR PATENT WILL ISSUE
Topics:


Related Articles
CAMBRIDGE NEUROSCIENCE REPORTS FIRST QUARTER RESULTS
CAMBRIDGE NEUROSCIENCE BEGINS HUMAN CLINICAL TRIALS OF NOVEL ANTI-STROKE COMPOUND
CAMBRIDGE NEUROSCIENCE EXPANDS CLINICAL STUDIES OF CERESTAT(TM) IN STROKE PATIENTS
CAMBRIDGE NEUROSCIENCE PRESENTS CONFIRMATORY CLINICAL RESULTS FOR CERESTAT(R) IN BRAIN INJURY PATIENTS
Cambridge NeuroScience Awarded Phase I SBIR Grant for Development of Novel Agents to Reverse Nerve Damage
Cambridge NeuroScience Initiates Second Phase I Study of CNS 5161 and Announces Successful Completion of First Phase I Trial
Cambridge NeuroScience Reports Positive Results From Pain Study
CeNeS Pharmaceuticals plc and Cambridge NeuroScience Inc. Agree to Merge.
Cambridge NeuroScience Obtains Exclusive Rights to Neuregulin-2 Growth Factor From Harvard University.
Cambridge NeuroScience Awarded a Phase II SBIR Grant for Discovery of Drugs to Treat Peripheral Nerve Dysfunction.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters